Advisory Board
Guiding Strategy. Shaping Innovation. Advancing Science.
Our Advisory Board brings together a distinguished group of industry leaders and subject matter experts in cellular therapy. Their guidance helps shape our strategic direction, ensuring we remain at the forefront of innovation while maintaining the highest standards of quality and service.
Amittha Wickrema, Ph.D.
Professor of Medicine, Director, Advanced Cellular Therapeutics Facility & Faculty Director, cGMP Cell & Tissue Manipulation Core Facility, University of Chicago.
Co-Founder, CellSecure Bio, Inc., with extensive experience in the field of Cellular Therapy. Former FACT inspector for accreditation of cellular therapy programs. Expertise in designing, building, and operationalizing clinical cellular therapy manufacturing and manipulation facilities. Co-investigator in numerous IND applications related to cellular therapy development and manufacturing.
Amit Verma, M.D.
Chair Department of Oncology, and Professor of Medicine and Developmental & Cell Biology, Montefiore Albert Einstein College of Medicine, Bronx, NY.
A world authority in blood cancer therapy and research. Instrumental in bringing novel therapies for Myelodysplastic syndromes (MDS) to patients. Pioneer in enabling point-of-care cell therapy at Einstein College of Medicine. Founder of several biotech start-up companies in New York.
Andrew Artz, M.D.
Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Director, Aging and Blood Cancers Program, Deputy Director of Outcomes, Center for Cancer and Aging. City of Hope Cancer Center, Los Angeles, CA.
A pioneer in Blood Stem Cell Transplantation in older adults. Andrew Artz, M.D., is a renowned clinician and researcher in the field of aging, Hematologic Malignancies, Cellular Therapy, and Anemia. His research aims to expand the use of curative-intent transplants and cellular therapy for older adults.
Dr. Feldman is the Site Head and Scientific Director of the Stanford University GMP Cell and Gene Therapy facility. He oversees and directs process development and manufacturing operations to produce cellular therapy products for the treatment of cancers and rare diseases. His research interests include development of novel viral vectors, closed manufacturing systems, and clinically suitable reagents for cell therapy applications. He has extensive experience in the development and manufacturing of CAR-T cells, TILs, and other one-of-a-kind cell therapy products for treating patients under Investigational New Drug applications.
RESOURCES
See Our Latest News
Custom Solutions Based Around Clients Needs
Connect with our experts to learn how CellSecure Bio secures critical materials and helps accelerate cell therapy programs.